Possible reasons for the inefficacy of genetically engineered biological agents in rheumatoid arthritis and ways of its prevention

Genetically engineered biological agents (GEBAs) have held a firm place in the treatment of rheumatoid arthritis (RA). Patients are selected for this treatment in accordance with international and Russian guidelines. The question as to whether GEBAs should be added to therapy with disease-modifying...

Celý popis

Podrobná bibliografie

Hlavní autor:	Natalia Vladimirovna Chichasova
Médium:	Artigo
Jazyk:	Russo
Vydáno:	IMA-PRESS LLC 2012-06-01
Edice:	Современная ревматология
Témata:	rheumatoid arthritis genetically engineered biological agents disease-modifying anti-rheumatic drugs therapy efficiency
On-line přístup:	https://mrj.ima-press.net/mrj/article/view/410
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!